首页> 外文OA文献 >Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study
【2h】

Chinese Herbal Medicine Ameliorated the Development of Chronic Kidney Disease in Patients with Chronic Hepatitis C: A Retrospective Population-Based Cohort Study

机译:中草药改善了慢性丙型肝炎患者慢性肾病的发展:一种回顾性的基于人群的队列研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chronic kidney disease (CKD) is a serious complication affecting patients with chronic hepatitis. The effectiveness of CHM for the prevention of CKD in hepatitis patients remains unclear. Therefore, we conducted a retrospective cohort study to investigate the effectiveness of CHM in preventing the development of CKD in hepatitis patients. From a subdataset of the Taiwan National Health Insurance Research Database (NHIRD), we included 19,409 patients newly diagnosed with hepatitis B and hepatitis C between the years 2000 and 2010. After exclusion criteria and 1 : 1 propensity score matching process, we compared demographic factors, comorbidities, and correlated drugs between the CHM and non-CHM cohorts. Statistical analysis was applied to evaluate the differences in characteristic distributions and to compare the cumulative incidence of CKD between the CHM and non-CHM cohorts. This study showed that the patients suffering from hepatitis C with CHM treatment more than 90 days as an adjuvant therapy combined with western medical treatment modalities exhibited a decreased risk of developing CKD (hazard ratio (HR) = 0.40, 95% confidence interval (CI) = 0.21–0.76, p value <0.01). The Kaplan–Meier curve revealed a lower cumulative incidence rate of CKD (p value = 0.004) for the CHM cohort. For further reference, we herein offer the ten most frequently prescribed single herbs and herbal formulas; as such, Salviae miltiorrhizae and Jia-Wei-Xiao-Yao-San were the most commonly prescribed single herb and formula, respectively. This nationwide retrospective cohort study provides evidence that CHM is an effective adjuvant treatment to decrease the risk of developing CKD in hepatitis C patients.
机译:慢性肾病(CKD)是影响慢性肝炎患者的严重并发症。 CHM在肝炎患者中预防CKD的有效性仍不清楚。因此,我们进行了回顾性队列研究,探讨CHM在预防肝炎患者中CKD发育的有效性。从台湾国家健康保险研究数据库(纳米尔)的子田间,我们包括19,409名患者在2000年和2010年之间进行了新诊断患有乙型肝炎和丙型肝炎的患者。排除标准和1:1倾向得分匹配过程后,我们比较了人口因子CHM和非CHM队列之间的合并症和相关药物。应用统计分析来评估特征分布的差异,并比较CKD与非CHM队列之间CKD的累积发生率。本研究表明,患有CHM治疗的丙型肝炎的患者超过90天,随着佐剂治疗与西方医疗方式相结合,表现出CKD的开发风险降低(危害比(HR)= 0.40,95%置信区间(CI) = 0.21-0.76,p值<0.01)。 KAPLAN-MEIER曲线对于CHM队列显示CKD的累积发生率较低(P值= 0.004)。为了进一步参考,我们在此提供十个最常规定的单一草药和草药公式;因此,Salviae Miltiorrhizae和Jia-Wei-Xiao-yao-SAN分别是最常见的单人草药和公式。本国回顾性队列研究提供了CHM的证据表明CHM是一种有效的佐剂治疗,以降低丙型肝炎患者在CKD中发展CKD的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号